Amylyx Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Amylyx Pharmaceuticals, Inc.
28.35
−0.85 · −2.90%
+10.71%
vs ±25.6% implied · ×0.42
shaded = implied · ▲▼ = realized
Bull1
Bear3
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $300.4M | 14.45% | +0.59% |
| BlackRockindex-like | $158.5M | 7.63% | −0.02% |
| Perceptive | $149.7M | 7.20% | +0.60% |
| TCG Crossover | $112.1M | 5.39% | 0.00% |
| Commodore Capital | $101.5M | 4.88% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $300.4M | 14.45% | +0.59% |
| BlackRockindex-like | $158.5M | 7.63% | −0.02% |
| Perceptive | $149.7M | 7.20% | +0.60% |
| TCG Crossover | $112.1M | 5.39% | 0.00% |
| Commodore Capital | $101.5M | 4.88% | 0.00% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Amylyx Pharmaceuticals, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Amylyx Pharmaceuticals, Inc.'s 6 closest co-movers, none share that code.
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Expected move
Inputsspot 29.20exp Nov 20ATM strike 29ATM straddle 3.55IV 71%